Risks and benefits of combined use of bucolome and warfarin in anticoagulation therapy

International Heart Journal

Volumn 51, Issue 6, 2010, Pages 399-403

  Hatakeyama, Yuko ^a   Niwano, Shinichi ^a   Niwano, Hiroe ^a   Kosukegawa, Tomoko ^a   Izumi, Tohru ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anticoagulation; Bucolome; TTR; Warfarin

Indexed keywords

BUCOLOME; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN INFARCTION; CONTROLLED STUDY; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTHETIC VALVE THROMBOSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

AGED; ANTICOAGULANTS; BARBITURATES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 78650622166     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.51.399     Document Type: Article

References (19)

1. Baglin TP, Keeling DM, Watson HG, British Committee for Standards in Haematology. Guidelines on oral anticoagulation (warfarin): third edition--2005 update. Br J Haematol 2006; 132: 277-285.
2. Singer DE, Chang Y, Fang MC, et al. The net clinical beneft of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151: 297-305.
3. Piccini JP, Patel MR, Mahaffey KW, Fox KA, Califf RM. Rivar-oxaban, an oral direct factor Xa inhibitor. Expert Opin Investig Drugs 2008; 17: 925-37. (Review)
4. Turpie AG. New oral anticoagulants in atrial fibrillation. Eur Heart J 2008; 29: 155-165. (Review)
5. Li J, Wang S, Barone J, Malone B. Warfarin pharmacogenomics. PT 2009; 34: 422-427.
6. Pérez-Andreu V, Roldán V, González-Conejero R, Hernández-Romero D, Vicente V, Marín F. Implications of pharmacogenetics for oral anticoagulants metabolism. Curr Drug Metab 2009; 10: 632-42.
7. Jarvis S, Li C, Bogle RG. Possible interaction between pomegranate juice and warfarin. Emerg Med J 2010; 27: 74-5.
8. Takahashi H, Kashima T, Kimura S, et al. Pharmacokinetic interaction between warfarin and a uricosuric agent, bucolome: application of In vitro approaches to predicting In vivo reduction of (S)-warfarin clearance. Drug Metab Dispos 1999; 27: 1179-86.
9. Osawa M, Hada N, Matsumoto K, et al. Usefulness of coadminis-tration of bucolome in warfarin therapy: pharmacokinetic and pharmacodynamic analysis using outpatient prescriptions. Int J Pharm 2005; 293: 43-9.
10. Schmitt L, Speckman J, Ansell J. Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. J Thromb Thrombolysis 2003; 15: 213-6.
11. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-9.
12. Ogawa S, Aizawa Y, Atarashi H, et al. Guidelines for management of anticoagulant and antiplatelet therapy in cardiovascular disease. Circ J 2008; 72 (Suppl IV): 1601-8.
13. Loeliger EA. Laboratory control, optimal therapeutic ranges and therapeutic quality control in oral anticoagulation. Acta Haematol 1985; 74: 125-131. (Review)
14. Rose AJ, Ozonoff A, Berlowitz DR, Henault LE, Hylek EM. Warfarin dose management affects INR control. J Thromb Haemost 2009; 7: 94-101.
15. Kim YK, Nieuwlaat R, Connolly SJ, et al. Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study. J Thromb Haemost 2010; 8: 101-6.
16. Matsumoto K, Ishida S, Ueno K, et al. The stereoselective effects of bucolome on the pharmacokinetics and pharmacodynamics of racemic warfarin. J Clin Pharmacol 2001; 41: 459-64.
17. Takigawa T, Tainaka H, Mihara K, Ogata H. Inhibition of S-war-farin metabolism by nonsteroidal antiinflammatory drugs in human liver microsomes in vitro. Biol Pharm Bull 1998; 21: 541-3.
18. Edwin SB, Jennings DL, Kalus JS. An evaluation of the early pharmacodynamic response after simultaneous initiation of warfarin and amiodarone. J Clin Pharmacol 2010; 50: 693-8.
19. Murosaki N, Senoh H, Takemoto M. Intraluminal ureteral hematoma complicating anticoagulant therapy. Nippon Hinyokika Gakkai Zasshi 2005; 96: 564-7. (Japanese)